---
title: "Kyverna Therapeutics, Inc. (KYTX.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/KYTX.US.md"
symbol: "KYTX.US"
name: "Kyverna Therapeutics, Inc."
industry: "Biotechnology"
datetime: "2026-05-21T05:35:07.813Z"
locales:
  - [en](https://longbridge.com/en/quote/KYTX.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/KYTX.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/KYTX.US.md)
---

# Kyverna Therapeutics, Inc. (KYTX.US)

## Company Overview

Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [kyvernatx.com](https://kyvernatx.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -3.32 | 309 | - | - | - |
| PB | 2.65 | 231 | 2.96 | 1.96 | 0.78 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-15T04:00:00.000Z

Total Analysts: **6**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 4 | 67% |
| Overweight | 2 | 33% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 8.57 |
| Highest Target | 33.00 |
| Lowest Target | 25.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/KYTX.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/KYTX.US/norm.md)
- [Related News](https://longbridge.com/en/quote/KYTX.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/KYTX.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**